00:06 , Apr 6, 2019 |  BioCentury  |  Finance

Big caps under pressure

Biogen’s fall in the wake of its decision to discontinue late-stage trials of Alzheimer’s therapy aducanumab is yet another reminder that large caps are in dire need of new pipeline products, and could serve as...
14:30 , Mar 19, 2019 |  BC Innovations  |  Distillery Therapeutics

ALK2 inhibition for diffuse intrinsic pontine glioma

DISEASE CATEGORY: Cancer INDICATION: Brain cancer Cell culture and mouse studies suggest inhibiting ALK2 could help treat diffuse intrinsic pontine glioma (DIPG) in patients harboring activating ALK2 mutations. In tumorspheres derived from an ALK2-mutant mouse...
22:56 , Jan 25, 2019 |  BioCentury  |  Finance

Venrock spreads HAE bets

Venrock is broadening its portfolio of oral hereditary angioedema therapy investments by leading a $23 million series B round that will allow Attune Pharmaceuticals to move its lead plasma kallikrein (KLKB1) inhibitor into Phase II...
02:49 , Jan 5, 2019 |  BioCentury  |  Finance

Ready to launch

  The proposed $74 billion takeout of Celgene Corp. by Bristol-Myers Squibb Co. will not shift buysider attention away from upcoming and maturing drug launches heading into 2019, with plenty to track following a record...
20:02 , Nov 2, 2018 |  BC Week In Review  |  Financial News

With clear FDA path, Clementia raises $70.2M

Days after revealing regulatory plans for its therapy for a rare bone disease, Clementia Pharmaceuticals Inc. (NASDAQ:CMTA) raised $70.2 million in a bumped-up follow-on offering. Clementia priced 5.3 million shares at $13.25 late Oct. 29,...
14:43 , Oct 30, 2018 |  BC Extra  |  Financial News

With clear FDA path, Clementia raises $70.2M

Days after revealing regulatory plans for its therapy for a rare bone disease, Clementia Pharmaceuticals Inc. (NASDAQ:CMTA) raised $70.2 million in a bumped-up follow-on offering. Clementia priced 5.3 million shares at $13.25 late Monday, hours...
19:52 , Oct 26, 2018 |  BC Week In Review  |  Clinical News

Clementia jumps on NDA plans for unmet rare bone disease

Clementia Pharmaceuticals Inc. (NASDAQ:CMTA) climbed $4.16 (40%) to $14.50 on Oct. 24 after announcing regulatory plans for palovarotene that could put the therapy first in line to gain FDA approval for fibrodysplasia ossificans progressiva (FOP)....
22:55 , Oct 25, 2018 |  BC Innovations  |  Targets & Mechanisms

Blueprint for selectivity

Blueprint Medicines Corp. is making the jump from cancer to rare disease with an inhibitor for the rare pediatric bone disease FOP that sets the company up against at least two competitors further ahead in...
21:06 , Oct 24, 2018 |  BC Extra  |  Company News

Clementia jumps on NDA plans for unmet rare bone disease

Clementia Pharmaceuticals Inc. (NASDAQ:CMTA) climbed $4.16 (40%) to $14.50 on Wednesday after announcing regulatory plans for palovarotene that could put the therapy first in line to gain FDA approval for fibrodysplasia ossificans progressiva (FOP). Clementia...
19:27 , Oct 5, 2018 |  BC Week In Review  |  Clinical News

Blueprint debuts selective ALK2 inhibitor for rare musculoskeletal disease

Blueprint Medicines Corp. (NASDAQ:BPMC) provided the first glimpse of its preclinical ALK2 inhibitor program, BLU-782, when it presented data at the American Society for Bone and Mineral Research (ASBMR) meeting in Montreal on Sept. 30....